Acute and long-term (2-years) clinical outcomes of the CoreValve 31mm in large aortic annuli: A multicenter study

GF Attizzani, Y Ohno, A Latib, AS Petronio, C Giannini, F Ettori, S Curello, F Bedogni, D Todaro, N Brambilla, G Bruschi, P Colombo, P Presbitero, R Fiorilli, A Poli, P Martina, A Colombo, M Barbanti, C Tamburino

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

INTRODUCTION: Little is known about the early and late performance of the 31mm CoreValve Revalving System (CRS, Medtronic Inc., Galway, Ireland). Our aim was to compare acute and long-term results of the 31mm CRS with other valve sizes. METHODS: Consecutive patients undergoing transcatheter aortic valve implantation (TAVI) with CRS in nine Italian centers were prospectively included and dichotomized according to prosthesis size in two different groups, as follows: 31mm and other valve sizes (i.e., 23, 26, and 29mm combined). End points were defined according to Valve Academic Research Consortium definitions. Propensity score matching was performed. RESULTS: In total, 2069 patients (n=169 [8%] in the 31mm group and n=1900 [92%] in the other valve sizes group) were included. After propensity matching, the implantation of the 31mm valve was associated with lower rates of procedural- (91.3% vs. 98.1%, p=0.030) and device-success (88.5% vs. 97.1%, p=0.016), longer procedural time (120 [80-180] min. vs. 90 [60-120] min., p
Original languageEnglish
Pages (from-to)543-549
Number of pages7
JournalInternational Journal of Cardiology
Volume227
Issue number13
DOIs
Publication statusPublished - 2017

Fingerprint

Multicenter Studies
Propensity Score
Ireland
Prostheses and Implants
Equipment and Supplies
Research
Transcatheter Aortic Valve Replacement

Cite this

Acute and long-term (2-years) clinical outcomes of the CoreValve 31mm in large aortic annuli: A multicenter study. / Attizzani, GF; Ohno, Y; Latib, A; Petronio, AS; Giannini, C; Ettori, F; Curello, S; Bedogni, F; Todaro, D; Brambilla, N; Bruschi, G; Colombo, P; Presbitero, P; Fiorilli, R; Poli, A; Martina, P; Colombo, A; Barbanti, M; Tamburino, C.

In: International Journal of Cardiology, Vol. 227, No. 13, 2017, p. 543-549.

Research output: Contribution to journalArticle

Attizzani, GF, Ohno, Y, Latib, A, Petronio, AS, Giannini, C, Ettori, F, Curello, S, Bedogni, F, Todaro, D, Brambilla, N, Bruschi, G, Colombo, P, Presbitero, P, Fiorilli, R, Poli, A, Martina, P, Colombo, A, Barbanti, M & Tamburino, C 2017, 'Acute and long-term (2-years) clinical outcomes of the CoreValve 31mm in large aortic annuli: A multicenter study', International Journal of Cardiology, vol. 227, no. 13, pp. 543-549. https://doi.org/10.1016/j.ijcard.2016.10.104
Attizzani, GF ; Ohno, Y ; Latib, A ; Petronio, AS ; Giannini, C ; Ettori, F ; Curello, S ; Bedogni, F ; Todaro, D ; Brambilla, N ; Bruschi, G ; Colombo, P ; Presbitero, P ; Fiorilli, R ; Poli, A ; Martina, P ; Colombo, A ; Barbanti, M ; Tamburino, C. / Acute and long-term (2-years) clinical outcomes of the CoreValve 31mm in large aortic annuli: A multicenter study. In: International Journal of Cardiology. 2017 ; Vol. 227, No. 13. pp. 543-549.
@article{950517abbe3540a091438d23ff027c0b,
title = "Acute and long-term (2-years) clinical outcomes of the CoreValve 31mm in large aortic annuli: A multicenter study",
abstract = "INTRODUCTION: Little is known about the early and late performance of the 31mm CoreValve Revalving System (CRS, Medtronic Inc., Galway, Ireland). Our aim was to compare acute and long-term results of the 31mm CRS with other valve sizes. METHODS: Consecutive patients undergoing transcatheter aortic valve implantation (TAVI) with CRS in nine Italian centers were prospectively included and dichotomized according to prosthesis size in two different groups, as follows: 31mm and other valve sizes (i.e., 23, 26, and 29mm combined). End points were defined according to Valve Academic Research Consortium definitions. Propensity score matching was performed. RESULTS: In total, 2069 patients (n=169 [8{\%}] in the 31mm group and n=1900 [92{\%}] in the other valve sizes group) were included. After propensity matching, the implantation of the 31mm valve was associated with lower rates of procedural- (91.3{\%} vs. 98.1{\%}, p=0.030) and device-success (88.5{\%} vs. 97.1{\%}, p=0.016), longer procedural time (120 [80-180] min. vs. 90 [60-120] min., p",
author = "GF Attizzani and Y Ohno and A Latib and AS Petronio and C Giannini and F Ettori and S Curello and F Bedogni and D Todaro and N Brambilla and G Bruschi and P Colombo and P Presbitero and R Fiorilli and A Poli and P Martina and A Colombo and M Barbanti and C Tamburino",
year = "2017",
doi = "10.1016/j.ijcard.2016.10.104",
language = "English",
volume = "227",
pages = "543--549",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "13",

}

TY - JOUR

T1 - Acute and long-term (2-years) clinical outcomes of the CoreValve 31mm in large aortic annuli: A multicenter study

AU - Attizzani, GF

AU - Ohno, Y

AU - Latib, A

AU - Petronio, AS

AU - Giannini, C

AU - Ettori, F

AU - Curello, S

AU - Bedogni, F

AU - Todaro, D

AU - Brambilla, N

AU - Bruschi, G

AU - Colombo, P

AU - Presbitero, P

AU - Fiorilli, R

AU - Poli, A

AU - Martina, P

AU - Colombo, A

AU - Barbanti, M

AU - Tamburino, C

PY - 2017

Y1 - 2017

N2 - INTRODUCTION: Little is known about the early and late performance of the 31mm CoreValve Revalving System (CRS, Medtronic Inc., Galway, Ireland). Our aim was to compare acute and long-term results of the 31mm CRS with other valve sizes. METHODS: Consecutive patients undergoing transcatheter aortic valve implantation (TAVI) with CRS in nine Italian centers were prospectively included and dichotomized according to prosthesis size in two different groups, as follows: 31mm and other valve sizes (i.e., 23, 26, and 29mm combined). End points were defined according to Valve Academic Research Consortium definitions. Propensity score matching was performed. RESULTS: In total, 2069 patients (n=169 [8%] in the 31mm group and n=1900 [92%] in the other valve sizes group) were included. After propensity matching, the implantation of the 31mm valve was associated with lower rates of procedural- (91.3% vs. 98.1%, p=0.030) and device-success (88.5% vs. 97.1%, p=0.016), longer procedural time (120 [80-180] min. vs. 90 [60-120] min., p

AB - INTRODUCTION: Little is known about the early and late performance of the 31mm CoreValve Revalving System (CRS, Medtronic Inc., Galway, Ireland). Our aim was to compare acute and long-term results of the 31mm CRS with other valve sizes. METHODS: Consecutive patients undergoing transcatheter aortic valve implantation (TAVI) with CRS in nine Italian centers were prospectively included and dichotomized according to prosthesis size in two different groups, as follows: 31mm and other valve sizes (i.e., 23, 26, and 29mm combined). End points were defined according to Valve Academic Research Consortium definitions. Propensity score matching was performed. RESULTS: In total, 2069 patients (n=169 [8%] in the 31mm group and n=1900 [92%] in the other valve sizes group) were included. After propensity matching, the implantation of the 31mm valve was associated with lower rates of procedural- (91.3% vs. 98.1%, p=0.030) and device-success (88.5% vs. 97.1%, p=0.016), longer procedural time (120 [80-180] min. vs. 90 [60-120] min., p

U2 - 10.1016/j.ijcard.2016.10.104

DO - 10.1016/j.ijcard.2016.10.104

M3 - Article

VL - 227

SP - 543

EP - 549

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 13

ER -